Human ferritin results
Reported pilot outcomes.
“In pilot studies, PVP+Iron raised ferritin levels on average 25.7 ng/mL in 30 days.”
“In cases where baseline ferritin was below normal range, PVP+Iron brought it into normal range, >30.”
“A nine-person, 30-day pilot reported increased ferritin at a materially lower elemental-iron dose, with no side effects reported.”
“Having overcome the challenges of extraction and molecular size via fractionalization of phosvitin, PVP+Iron provides 30-day results, an average increase in ferritin of 25.7 ng/mL during that time frame, with no side effects reported.”
| Subject | Baseline ferritin | Day 30 ferritin | Increase | % increase | Iron / day | Side effects |
|---|---|---|---|---|---|---|
| 001 | 8 ng/mL | 50 ng/mL | +42 ng/mL | 525% | 18 mg | None |
| 002 | 21 ng/mL | 65 ng/mL | +44 ng/mL | 210% | 16 mg | None |
| 004 | 11 ng/mL | 32 ng/mL | +21 ng/mL | 191% | 16 mg | None |
| 007 | 16 ng/mL | 44 ng/mL | +28 ng/mL | 175% | 16 mg | None |
| 009 | 14 ng/mL | 41 ng/mL | +27 ng/mL | 193% | 16 mg | None |
Across all nine pilot participants, ferritin increased, and the table records “None” under side effects for every participant. Source: Beyond Nutraceuticals / Ecovatec nine-person, 30-day PVP+Iron pilot.
Laboratory absorption and transport
What the intestinal-cell work reported.
“Louisiana State University Caco-2 intestinal-cell work reported up to 813% greater iron uptake in the presence of phosvitin peptides.”
“Up to an 813% greater iron absorption into enterocytes.”
“Phosvitin phosphopeptides increase iron uptake in a Caco-2 cell monolayer model.”
“The combination of 10 μg/mL Fe : 2 μg/mL PVP synthesized more ferritin than any other combination.”
Dose efficiency
More ferritin from less iron.
“Compared to standard irons, PVP+Iron produced a greater increase in ferritin, with lower doses, in a shorter period of time, with no side effects.”
“PVP+Iron achieved an average ferritin increase of 25.7 ng/mL over four weeks using 16 mg of elemental iron per day.”
“The PVP+Iron pilot reported a 115.2% increase in ferritin over four weeks.”
“When expressed as ferritin increase per month per milligram of iron, PVP+Iron produced 1.606 ng/mL, compared with a maximum of 0.138 ng/mL among the cited iron-salt studies.”
Contextual benchmarks — ferritin increase per month per mg of iron
Iron salts
≈1100% greater
- PVP+Iron
- 1.606 ng/mL
- Iron salts
- 0.138 ng/mL
PVP+Iron: 115% ferritin increase per month; iron salts: 11%.
Source: Cross-study calculated benchmark; underlying comparator study still to be identified.
Iron bisglycinate
≈470% greater
- PVP+Iron
- 1.606 ng/mL
- Iron bisglycinate
- 0.341 ng/mL
PVP+Iron: 115% ferritin increase per month; iron bisglycinate: 28%.
Source: Cross-study calculated benchmark; underlying comparator study still to be identified.
Iron polysaccharide
3400% greater
- PVP+Iron
- 1.606 ng/mL
- Iron polysaccharide
- 0.047 ng/mL
PVP+Iron used 16 mg of iron over four weeks and reported a 25.7 ng/mL ferritin increase; the cited polysaccharide study used 150 mg over 12 weeks and reported a 21.1 ng/mL increase.
Source: Cross-study calculated benchmark; underlying comparator study still to be identified.
“The cross-study comparisons are presented for contextual benchmarking only and do not constitute a head-to-head comparative trial. A controlled comparative study is recommended to substantiate the early findings.
Tolerability and unabsorbed iron
Less reactive iron left behind.
“No significant side effects reported to date.”
“No side effects were reported by any participant in the nine-person, 30-day pilot.”
“Up to 98% reduction in unabsorbed iron that causes side effects and poses health risks.”
“More iron available for absorption. Less reactive iron left behind.”
“By binding iron, holding it soluble and limiting premature oxidation, the platform is intended to improve absorption while reducing disruption to the gut.”
Oxidation and iron availability
Why it stays absorbable.
“Up to a 98.7% decline in oxidation of highly absorbing Fe²⁺ to poorly absorbing Fe³⁺ in the gut.”
“Studies have reported that each phosvitin phosphopeptide can dynamically bond with up to 60 Fe²⁺ ions, keeping them soluble and preventing them from oxidizing to Fe³⁺ and subsequently forming insoluble complexes.”
“Phosvitin-derived peptides bind iron and hold it soluble and usable through digestion.”
“A strong concentration of soluble iron drives diffusion to the intestinal surface, where more absorbable iron is presented at the site of uptake.”
“Strong concentration gradients from PVP's dynamic bonding with iron ions allow for greater ion migration to and through tight junctions.”
Beyond iron
Broader phosvitin potential.
“Phosvitin binds multiple minerals, so the same delivery approach extends across nutrition.”
“PVP technology can be used for increasing the absorption of other minerals such as calcium, magnesium, zinc, copper, manganese and cobalt.”
“Studies have reported that PVPs interact with up to ten times more iron than casein phosphopeptides, due to PVP's greater number of phosphorylated serine amino acids.”
“Emerging research indicates possible antioxidant, anti-inflammatory, anti-microbial and other biological activities.”
The essential qualification
Early signal, not definitive clinical proof.
“The completed work is a signal, not definitive clinical proof. This financing funds the proof.”
“Beyond currently has enough evidence to justify controlled validation, but the completed work should not be presented as equivalent to definitive clinical evidence.”
“The cross-study comparisons are presented for contextual benchmarking only and do not constitute a head-to-head comparative trial. A controlled comparative study is recommended to substantiate the early findings.”